PGHL vs PPLPHARMA: Stock Comparison

Procter & Gamble Health Limited vs Piramal Pharma Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Piramal Pharma Limited is the larger company by market capitalisation. Procter & Gamble Health Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Piramal Pharma Limited shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Procter & Gamble Health Limited and Piramal Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, PGHL is more favourable on 11 of 13 scored metrics and PPLPHARMA on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹23,554 Cr vs ₹11,172 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-75.43x vs 34.28x
P/B Ratio
PPLPHARMA has a lower P/B
3.01x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹-2.45
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.08%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs -0.1%
EPS Growth (TTM YoY)
PGHL has faster EPS growth
54.6% vs 0%
Qtr Sales Growth
PGHL has stronger quarterly sales growth
19.1% vs -0.08%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricPGHLPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricPGHLPPLPHARMA
Live Price₹6,745.5₹177.1
Day Change-0.5%-4.17%
Volume4,59079 L
52-Week High₹6,975₹212.39
52-Week Low₹4,707₹132.3
Distance from 52W High-3.29%-16.62%

Valuation

MetricPGHLPPLPHARMA
Market Cap₹11,172 Cr₹23,554 Cr
P/E Ratio34.28x-75.43x
P/B Ratio21.36x3.01x
EPS₹196.64₹-2.45
Book Value₹316.01₹64.78
Dividend Yield2.34%0.08%

Growth

MetricPGHLPPLPHARMA
Revenue Growth (TTM YoY)19.1%-0.1%
EPS Growth (TTM YoY)54.6%0%
Qtr Sales Growth19.1%-0.08%
Qtr Profit Growth54.6%-25%

Profitability & Leverage

MetricPGHLPPLPHARMA
ROE61.6%-3.83%
ROCE83.5%2.52%
Net Margin23.22%-3.68%
Operating Margin32.4%10.4%
Debt to Equity0.02x0.7x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricPGHLPPLPHARMA
Promoter Holding0%34.86%
FII Holding6.33% 0.13 pp30.18% 0.52 pp
DII Holding12.44% 1.23 pp15.61% 0.08 pp
Public Holding29.42% 1.11 pp19.01% 0.34 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Procter & Gamble Health Limited and Piramal Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.